MedPath

A study to assess the effectiveness of cetrizine as an additional therapeutic agent to standard therapy,in comparison to placebo in limited patchy alopecia areata

Phase 3
Conditions
Health Condition 1: L639- Alopecia areata, unspecified
Registration Number
CTRI/2021/03/031832
Lead Sponsor
DrSarithaM
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

All patients diagnosed by consensus by investigators having limited patchy alopecia areata.

Exclusion Criteria

Patients on steroids or immunosuppressants for any other condition.

Pregnancy & lactation

Children less than 18 years

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath